摘要
酒石酸溴莫尼定是第三代α2-肾上腺素能受体激动剂,通过减少房水生成和增加葡萄膜巩膜途径的房水外流在青光眼和高眼压症的治疗中显示出降低眼压的效果,并可能通过增强视网膜神经节细胞的存活机制或诱导神经元存活因子的表达等非眼压依赖途径发挥神经保护作用。此外,酒石酸溴莫尼定因激动突触前α2受体使去甲肾上腺素释放减少导致瞳孔开大肌松弛、瞳孔括约肌相对占优势展现出缩瞳效果,这使其有助于改善激光角膜屈光手术和人工晶状体植入术后患者的夜间视觉质量。
Brimonidine tartrate,a third-generation alpha-2 adrenergic receptor agonist,is widely used in the treatment of glaucoma and ocular hypertension.It lowers intraocular pressure(IOP)by reducing aqueous humor production and increasing uveoscleral outflow.Beyond its IOP-lowering effects,growing evidence suggests that brimonidine may also provide neuroprotection through IOP-independent mechanisms,such as enhancing retinal ganglion cell survival or inducing the expression of neuronal survival factors.Additionally,brimonidine induces miosis by activating presynaptic alpha-2 receptors,which reduces norepinephrine release,leading to relaxation of the iris dilator muscle and relative dominance of the sphincter muscle.This miotic effect offers clinical benefits in improving nighttime visual quality for patients following laser corneal refractive surgery and intraocular lens implantation.
作者
孙一诺
张守宽
张磊
Sun Yinuo;Zhang Shoukuan;Zhang Lei(Department of Ophthalmology,Binzhou Medical University Hospital,Binzhou Shandong 256603,China)
出处
《国际眼科纵览》
2025年第6期432-437,共6页
International Review of Ophthalmology
基金
山东省医学会科研项目(YXH2024ZM002)。
关键词
酒石酸溴莫尼定
降眼压
缩瞳
神经保护
Brimonidine tartrate
Intraocular pressure reduction
Miosis
Neuroprotection
